InnoCare is an emerging innovative drugs platform, poised to become China’s best chemical drug company covering immunology, I-O1 and oncology with sustainable innovative culture and seasoned team from global pharmaceutical companies.

InnoCare's BTK inhibitors outperform both domestic and foreign competitors in terms of safety and patient compliance (only one dosage a day), with potential to be best-in-class and clear path to regulatory approval in China around 2020.

Its R progress in FGFR4 inhibitors ranks first in China.